A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of ut...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362954/ https://www.ncbi.nlm.nih.gov/pubmed/10576659 http://dx.doi.org/10.1038/sj.bjc.6690801 |
_version_ | 1782153582777204736 |
---|---|
author | Huuhtanen, R L Wiklund, T A Blomqvist, C P Böhling, T O Virolainen, M J Tribukait, B Andersson, L C |
author_facet | Huuhtanen, R L Wiklund, T A Blomqvist, C P Böhling, T O Virolainen, M J Tribukait, B Andersson, L C |
author_sort | Huuhtanen, R L |
collection | PubMed |
description | A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of utmost importance to be able to screen for those patients who respond to the treatment. Since proliferating cells are more sensitive to chemotherapy than non-proliferative cells, we measured the proliferation rate of the primary tumour of 55 soft tissue sarcoma patients with locally advanced or metastatic disease by determining the flow cytometric S phase fraction and immunohistochemical Ki-67 and cyclin A scores. S phase fraction or Ki-67 score did not predict chemotherapy response or progression-free survival. A high cyclin A score, however, correlated with a better chemotherapy response (P = 0.02) and longer progression-free survival time (P = 0.04). Our results suggest that a high cyclin A score predicts chemotherapy sensitivity. © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2362954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23629542009-09-10 A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients Huuhtanen, R L Wiklund, T A Blomqvist, C P Böhling, T O Virolainen, M J Tribukait, B Andersson, L C Br J Cancer Regular Article A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of utmost importance to be able to screen for those patients who respond to the treatment. Since proliferating cells are more sensitive to chemotherapy than non-proliferative cells, we measured the proliferation rate of the primary tumour of 55 soft tissue sarcoma patients with locally advanced or metastatic disease by determining the flow cytometric S phase fraction and immunohistochemical Ki-67 and cyclin A scores. S phase fraction or Ki-67 score did not predict chemotherapy response or progression-free survival. A high cyclin A score, however, correlated with a better chemotherapy response (P = 0.02) and longer progression-free survival time (P = 0.04). Our results suggest that a high cyclin A score predicts chemotherapy sensitivity. © 1999 Cancer Research Campaign Nature Publishing Group 1999-11 /pmc/articles/PMC2362954/ /pubmed/10576659 http://dx.doi.org/10.1038/sj.bjc.6690801 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Huuhtanen, R L Wiklund, T A Blomqvist, C P Böhling, T O Virolainen, M J Tribukait, B Andersson, L C A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients |
title | A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients |
title_full | A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients |
title_fullStr | A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients |
title_full_unstemmed | A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients |
title_short | A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients |
title_sort | high proliferation rate measured by cyclin a predicts a favourable chemotherapy response in soft tissue sarcoma patients |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362954/ https://www.ncbi.nlm.nih.gov/pubmed/10576659 http://dx.doi.org/10.1038/sj.bjc.6690801 |
work_keys_str_mv | AT huuhtanenrl ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT wiklundta ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT blomqvistcp ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT bohlingto ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT virolainenmj ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT tribukaitb ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT anderssonlc ahighproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT huuhtanenrl highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT wiklundta highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT blomqvistcp highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT bohlingto highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT virolainenmj highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT tribukaitb highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients AT anderssonlc highproliferationratemeasuredbycyclinapredictsafavourablechemotherapyresponseinsofttissuesarcomapatients |